Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.
Source: US Top News and Analysis
Related Posts
Indian mobile giant Airtel raises $1 billion for data centers from Carlyle, other PE firms
Signaling rising global interest in India’s data‑center sector, Bharti Airtel has attracted private‑equity interest as…
The Tech Download: Reputational damage, supply chain issues and local investment. What’s next for Middle East tech?
A two-week ceasefire was agreed between the U.S. and Iran on Wednesday, prompting hopes of…
Here are 3 ways to ignite a rally in beaten-down bank stocks like Wells Fargo and Goldman
Private credit risks, mass AI adoption and the U.S.-Iran war have all weighed on banks…